Clayton Duncan
Principal investigator, leads Valanbio Therapeutics Inc.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$3.2MFederal grants as PI3 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $3.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Feb 23, 2021 | NIH | SBIR Phase II IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $794K | Valanbio Therapeutics Inc |
| Apr 16, 2020 | NIH | SBIR Phase II IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $797K | Valanbio Therapeutics Inc |
| Apr 16, 2020 | NIH | SBIR Phase II IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens | $1.6M | Valanbio Therapeutics Inc |
Peer ranks
Federal funding#564
Awards as PI#822
Patents#273
Companies
- Valanbio Therapeutics IncLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.